Quoin Pharmaceuticals, Ltd.QNRXNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank69
3Y CAGR+63.2%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+63.2%/yr
Quarterly compound
Percentile
P69
Within normal range
vs 3Y Ago
4.3x
Strong expansion
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q3 2025 | 11.25% |
| Q2 2025 | -13.63% |
| Q1 2025 | 121.85% |
| Q4 2024 | -8.56% |
| Q3 2024 | 99.20% |
| Q2 2024 | -33.64% |
| Q1 2024 | 6.36% |
| Q4 2023 | 9.70% |
| Q3 2023 | 21.38% |
| Q2 2023 | -42.74% |
| Q1 2023 | 78.08% |
| Q4 2022 | -17.76% |
| Q3 2022 | 2.59% |
| Q2 2022 | 23.68% |
| Q1 2022 | -41.64% |
| Q4 2021 | 287.26% |
| Q3 2021 | 8.66% |
| Q2 2021 | 321.36% |
| Q1 2021 | -51.14% |
| Q4 2020 | 346.88% |
| Q3 2020 | -0.00% |
| Q2 2020 | -65.73% |
| Q1 2020 | 0.00% |
| Q4 2019 | 0.00% |
| Q4 2018 | 0.00% |
| Q4 2017 | 0.00% |
| Q4 2016 | 0.00% |